Long Beach, CA – According to filings with the U.S. Securities and Exchange Commission, Anivive Lifesciences is raising $44,300,424.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Dylan Balsz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Anivive Lifesciences
Anivive is reinventing the drug development process in pet pharma. Our proprietary software accelerates the delivery of new, affordable treatments for pets. Backed by over $45 million in seed funding, Anivive has gained conditional approval for LAVERDIA-CA1 (verdinexor), the first oral tablet to treat canine lymphoma and created a specialty sales force dedicated to supporting veterinarians. Anivives pipeline includes 8+ first-in-class pharmaceuticals, biologics, and vaccines.

To learn more about Anivive Lifesciences, visit http://anivive.com/

Contact:
Dylan Balsz, Chief Executive Officer
833-264-8483
dbalsz@anivive.com
https://www.linkedin.com/in/dylan-balsz-91066220/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved